Abingdon HealthABDXF +1.78%49 3-Year ROIIC % is 1,018.26 as of Jun. 2025, which is 89% above its 10-year median of 537.97. GuruFocus rates ABDXF with a GF Score™ of 49/100 and a GF Value™ of $0.21 (Possible Value Trap). The stock has 7 warning signs investors should review. Among 203 Medical Diagnostics & Research companies, Abingdon Health ranks better than 95.07% on this metric.
3-Year Return on Invested Incremental Capital (3-Year ROIIC %) measures the change in earnings as a percentage of change in investment over 3-year.
Abingdon Health's 3-Year ROIIC % for the quarter that ended in Jun. 2025 was 1,018.26%. High ROIIC is generally an indication that your business is capital efficient or has a higher operating leverage.
The industry rank for Abingdon Health's 3-Year ROIIC % or its related term are showing as below:
ABDXF's 3-Year ROIIC % is ranked better than 95.07% of 203
companies
in the Medical Diagnostics & Research industry
Industry Median: 0.22
vs ABDXF: 1018.26
Abingdon Health (OTCPK:ABDXF) 3-Year ROIIC % Explanation
Return on Incremental Invested Capital (ROIIC) is an extension of Return on Investment Capital (ROIC). ROIC % tells investors how efficiently that profitability is earned per dollar of company capital. ROIIC narrows the focus even further and shows how profitable each additional unit of capital investment could be. ROIIC % is a more powerful metric than ROIC because it measures how much money the company can generate going forward on future capital investments.
High ROIIC is generally an indication that your business is capital efficient or has a higher operating leverage.
Be Aware
It's important to keep in mind that when tracking ROIIC, the metric is better suited to forecasting the trend of future returns rather than measuring current return on investment.
Abingdon Health 3-Year ROIIC % Related Terms
Abingdon Health 3-Year ROIIC % Historical Data
* Premium members only.
The historical data trend for Abingdon Health's 3-Year ROIIC % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
ABDXF vs TMO, DHR, IDXX: 3-Year ROIIC % Comparison
For the Diagnostics & Research subindustry, Abingdon Health's 3-Year ROIIC %, along with its competitors' market caps and 3-Year ROIIC % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Abingdon Health 3-Year ROIIC % vs Medical Diagnostics & Research Industry
For the Medical Diagnostics & Research industry and Healthcare sector, Abingdon Health's 3-Year ROIIC % distribution charts can be found below:
* The bar in red indicates where Abingdon Health's 3-Year ROIIC % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
** Annual data of NOPAT and Invested Capital was used to calculate 3-Year ROIIC %.
*** Please be aware that the ROIIC (Return on Invested Capital) calculations are based on company-level data using the primary share class. The calculated data provided is for demonstration purposes and may slightly differ from the results displayed in the title due to potential variations caused by currency exchange rate differences throughout the year.
Abingdon Health (ABDXF) has a 3-Year ROIIC % of 1,018.26 as of Jun. 2025. 3-Year ROIIC % measures the change in earnings as a percentage of change in investment over 3-year. View historical data on Abingdon Health and its competitors. This is 89% above median its historical median of 537.97. According to the industry distribution chart, Abingdon Health ranks #10 out of 203 companies in the Medical Diagnostics & Research industry, placing it in the top 4.9%.
Is Abingdon Health's 3-Year ROIIC % too high?
Abingdon Health's current 3-Year ROIIC % of 1,018.26 is 89% above median its 10-year median of 537.97. The Medical Diagnostics & Research industry median 3-Year ROIIC % is 0.22. Abingdon Health's value of 1,018.26 is 462745.5% above this industry median. Based on the distribution chart, Abingdon Health ranks #10 out of 203 companies in the Medical Diagnostics & Research industry, which is in the top quartile — a strong position relative to peers. Overall, Abingdon Health has a GF Score™ of 49/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Abingdon Health's 3-Year ROIIC % compare to TMO and DHR?
According to the Medical Diagnostics & Research industry distribution chart, Abingdon Health ranks #10 out of 203 companies for 3-Year ROIIC %. This places Abingdon Health in the top 5% of its industry — outperforming the majority of peers. The industry median 3-Year ROIIC % is 0.22. Abingdon Health's value of 1,018.26 is 462745.5% above this benchmark. While the company's 10-year median is 537.97 vs. the industry median of 0.22, Abingdon Health has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 3-Year ROIIC % for a Medical Diagnostics & Research company?
The median 3-Year ROIIC % among Medical Diagnostics & Research companies is 0.22, based on 203 companies in the industry. Companies in the top quartile (top 25%) have a 3-Year ROIIC % significantly above this median, while those in the bottom quartile fall well below. However, 3-Year ROIIC % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Abingdon Health's current 3-Year ROIIC % of 1,018.26 is 462745.5% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 3-Year ROIIC % mean?
A high 3-Year ROIIC % can signal that a stock is expensive relative to its fundamentals. 3-Year ROIIC % measures the change in earnings as a percentage of change in investment over 3-year. View historical data on Abingdon Health and its competitors. For the Medical Diagnostics & Research industry, the median 3-Year ROIIC % is 0.22 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Abingdon Health's current 3-Year ROIIC % is 1,018.26, which is 89% above median its own 10-year median of 537.97. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Abingdon Health stock overvalued right now?
Based on GuruFocus' analysis, Abingdon Health (ABDXF) is currently considered Possible Value Trap. The stock's GF Value™ is $0.21, compared to a current price of $0.14 — trading 34.6% below its estimated fair value. The current 3-Year ROIIC % is 1,018.26, which is 89% above median its 10-year median of 537.97 and 462745.5% above the Medical Diagnostics & Research industry median of 0.22. Abingdon Health's overall GF Score™ is 49/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 3-Year ROIIC % calculated?
3-Year ROIIC % is calculated from a company's financial statements. For Abingdon Health (ABDXF), the current 3-Year ROIIC % is 1,018.26 as of Jun. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Abingdon Health (ABDXF) Overvalued in 2026?
Based on GuruFocus' analysis, Abingdon Health stock appears to be undervalued.
The current stock price of $0.14 is trading 34.6% below its estimated GF Value™ of $0.21.
GuruFocus considers Abingdon Health to be Possible Value Trap.
Key valuation signals for ABDXF:
3-Year ROIIC %: 1,018.26 (89% above median its 10-year median of 537.97)
GF Value™: $0.21 vs. price of $0.14 (34.6% below fair value)
Industry Position: 462745.5% above the Medical Diagnostics & Research median (#10 of 203)
No single metric tells the full story. See the ABDXF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Abingdon Health PLC develops, manufactures, and distributes diagnostic devices and provides regulatory consultancy to diagnostics businesses. It offers integrated lateral flow CRO/CDMO services covering feasibility, manufacturing, packaging, kitting, documentation, and commercial support. Segments include Contract Development (milestone-based third-party work, revenue over time by completion), Contract Manufacturing (development/manufacturing via daily consultancy, revenue at customer control point), Product Sales (AbC-19TM, Pocket Diagnostic, PCRD tests, research antibodies, carriage; point in time), and Regulatory Services (IVD/medical device compliance, revenue over time), with key revenue from Regulatory Services. It operates in the UK, USA/Canada, Europe, and rest of world.
49GF Score
Get the complete analysis for ABDXF
3-Year ROIIC % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ABDXF has been successfully added to your 
